Fructosamine as the main glycemic marker for the diabetic patient in hemodialysis
DOI:
https://doi.org/10.15448/1983-652X.2016.2.22734Keywords:
diabetes mellitus, fructosamine, glycated hemoglobin, hemodialysis.Abstract
Introduction: Glycated hemoglobin (HbA1c) has been used since mid 70’s as a glycemic marker and it is, currently, adopted as the main glycemic marker to diabetes mellitus patients. However, many conditions make this accurate interpretation nearly impossible and it is required the use of another marker, fructosamine, which functions as the main and most accurate glycemic marker for hemodialytic patients with diabetes mellitus.
Objective: The present study aimed to review the literature regarding the use of fructosamine as the main and most accurate glycemic marker to the hemodialytic patient with diabetes mellitus.
Materials and Methods: It is an integrative literature review conducted by searching the databases Medline/Pubmed, Science Direct and Scielo. The following descriptors were used: diabetes mellitus, fructosamine, glycated hemoglobin and hemodialysis, as well as the combination of these words.
Results: From the 77 articles found, 04 studies were identified demonstrating the use fructosamine and HbA1c in hemodialytic patients with diabetes mellitus. From these evaluated studies, only one pointed the HbA1c as the best glycemic marker. However, almost half of the patients evaluated on that study were receiving intravenous iron doses to anemia treatment.
Conclusion: It possible to conclude that fructosamine is the most suited and the most accurate glycemic marker to hemodialytic patients with diabetes mellitus. Of the four selected articles, none of them was conducted in the Brazilian population, showing the importance of further studies about the use of fructosamine in hemodialytic patients with diabetes mellitus in Brazil.
References
Otunctemur A, Ozbek E, Sahin S, Dursun M, Besiroglu H, Koklu I, Erkoc M, Danis E, Bozkurt M, Gurbuz A. Diabetes mellitus as a risk factor for high grade renal cell carcinoma. Asian Pac J Cancer Prev. 2014;15(9):3993-6. http://dx.doi.org/10.7314/APJCP.2014.15.9.3993
Winkelmann ER, Fontela PC. Condições de saúde de pacientes com diabetes mellitus tipo 2 cadastrados na Estratégia Saúde da Família, em Ijuí, Rio Grande do Sul, 2010-2013. Epidemiol Serv Saúde. 2014;23(4):665-74. http://dx.doi.org/10.5123/S1679-49742014000400008
Prentki M, Nolan CJ. Islet b cell failure in type 2 diabetes. J Clin Invest. 2006 July;116(7):1802-12. http://dx.doi.org/10.1172/JCI29103
Nolan CJ, Augusto VD. Reversibility of defects in proinsulin processing and islet b-cell failure in obesity-related type 2 diabetes. Diabetes. 2016;65(2):352-4. http://dx.doi.org/10.2337/dbi15-0020
Juarez DT, Demaris KM, Goo R, Mnatzaganian CL, Smith HW. Significance of HbA1C and its measurement in the diagnosis of diabetes mellitus: US experience. Diabetes Metab Syndr Obes. 2014;7:487-94. http://dx.doi.org/10.2147/DMSO.S39092
Rahbar S, Blumenfeld O, Ranney HM. Studies of an unusual hemoglobin in patients with diabetes mellitus. Biochem Biophys Res Commun. 1969;36(5):838-43. http://dx.doi.org/10.1016/0006-291X(69)90685-8
Jeffcoate SL. Diabetes Control and Complications: the role of glycated heamoglobin, 25 years on. Diabet Med. 2004;21(7): 657-65. http://dx.doi.org/10.1046/j.1464-5491.2003.01065.x
Camargo JL, Gross JL. Glico-hemoglobina (HbA1c): Aspectos Clínicos e Analíticos. Arq Bras Endocrinol Metab. 2004;48:451-63. http://dx.doi.org/10.1590/S0004-27302004000400005
American Diabetes Association (ADA); Tests of glycemia in diabete: position statement. Diabetes Care. 2003;26:S106-8. http://dx.doi.org/10.2337/diacare.26.2007.S106
Calisti L, Tognetti S. Measure of glycosylated hemoglobin. Acta Biomed. 2005;76(3):59-62.
Henrichs HR. HbA1c-glycated Hemoglobin and Diabetes Mellitus. Bremen: UNI-MED; 2009.
Speeckaert M, Biesen WV, Delanghe J, Slingerland R, Wiecek A, Heaf J, Drechsler C, Lacatus R, Vanholder R, Nistor I. Are there better alternatives than heamoglobin A1c to estimate glycaemic control in the chronic kidney disease population? Nephrol Dial Transplant. 2014;29(12):2167-77. http://dx.doi.org/10.1093/ndt/gfu006
Armbruster DA. Fructosamine: structure, analysis, and clinical usefulness. Clin Chem. 1987;33(12):2153-63.
Nansseu JRN, Fokom-Domgue J, Noubiap JJN, Balti EV, Sobngwi E, Kengne AP. Fructosamine measurement for diabetes mellitus diagnosis and monitoring: a systematic review and metaanalysis protocol. BMJ Open. 2015;5(5):e007689. http://dx.doi.org/10.1136/bmjopen-2015-007689
Nagasaka Y, Fujii S, Yaga K, Matsumura S, Kaneko T. Clinical application of measuring serum fructosamine as an index of glycemic control in diabetic patients. Bull Yamaguchi Med. Sch. 1988; 35(3-4):59-62.
Reis ZSN, Miranda APB, Rezende CAL, Detofol RB, Costa CR, Cabral ACV. Rastreamento de cardiopatias congênitas associadas ao diabetes mellitus por meio da concentração plasmática materna de frutosamina. Rev Bras Ginecol Obstet. 2010;32(2):66-71. http://dx.doi.org/10.1590/S0100-72032010000200003
Radin MS. Pitfalls in hemoglobin A1c measurement: When results may be misleading. J Gen Intern Med. 2014;29(2):388-94. http://dx.doi.org/10.1007/s11606-013-2595-x
Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T, Okamura M, Okada S, Yamakawa T, Ishimura E, Nishizawa Y. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect or anemia and erythropoietin injection. J Am Soc Nephrol. 2007;18(3):896-903. http://dx.doi.org/10.1681/ASN.2006070772
World Health Organization. [Internet]. 2014. [acesso zm 2014 nov. 18]; Disponível em: http://www.who.int/mediacentre/factsheets/fs312/en/
King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025. Diabetes Care. 1998;21(9):1414-31. http://dx.doi.org/10.2337/diacare.21.9.1414
Ribeiro RCHM, Santiago E, Bertolin DC, Ribeiro DF, Cesarino CB, Burdmann EA. Depressão em idosos portadores de insuficiência renal crônica em tratamento hemodialítico. Acta Paul Enferm. 2009;22:505-8. http://dx.doi.org/10.1590/S0103-21002009000800010
Mehdi U, Toto RD. Anemia, diabetes, and chronic kidney disease. Diabetes Care. 2009;32(7):1320-6. http://dx.doi.org/10.2337/dc08-0779
Angelo BZ, Tessarollo C, Carvalho VD, Lemos TC, Koch MC, Maraschin JF. Fatores preditores de mortalidade em pacientes diabéticos em terapia de substituição renal em Tubarão -SC. ACM Arq Catarin Med. 2010;39(4):23-8.
Bouvet BR, Paparella CV, Arriaga SMM, Monje AL, Amarilla AM, Almará AM. Evaluation of urinary N-acetyl-betaD-glucosaminidase as a marker of early renal damage in patients with type 2 diabetes mellitus. Arq Bras Endocrinol Metab. 2014;58(8):798-801. http://dx.doi.org/10.1590/0004-2730000003010
Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, Kasiske B, Liu J, Mau LW, McBean M, Murray A, St Peter W, Guo H, Gustafson S, Li Q, Li S, Li S, Peng Y, Qiu Y, Roberts T, Skeans M, Snyder J, Solid C, Wang C, Weinhandl E, Zaun D, Arko C, Chen SC, Dalleska F, Daniels F, Dunning S, Ebben J, Frazier E, Hanzlik C, Johnson R, Sheets D, Wang X, Forrest B, Constantini E, Everson S, Eggers P, Agodoa L. US Renal Data System 2010 Annual Data Report. Am J Kidney Dis. 2011;57(1 Suppl 1):A8, e1-526. http://dx.doi.org/10.1053/j.ajkd.2010.10.007
American Diabetes Association. Standards of medical care in diabetes – 2012. Diabetes Care. 2012 Jan;35 Suppl 1:S11-63. http://dx.doi.org/10.2337/dc12-s011
Tzamaloukas AH, Friedman EA. Diabetes In: Daugirdas JT, Blake PG, Ing TS. Manual de diálise. 3ª ed. Rio de Janeiro: Medsi; 2003.
National Kidney Foundation. Anemia and Chronic Kidney Disease. 33th ed. New York: National Kidney Foundation; 2006-2007.
Abensur H. Deficiência de ferro na doença renal crônica. Rev Bras Hematol Hemoter. 2010;32(2):84-8. http://dx.doi.org/10.1590/s1516-84842010005000047
Draczevski L, Teixeira LM. Avaliação do perfil bioquímico e parâmetros hematológicos em pacientes submetidos à hemodiálise. Rev Saúde Pesq. 2011;4(1):15-22.
Bueno CR, Frizzo MN. Anemia na doença renal crônica em hospital da região noroeste do estado do Rio Grande do Sul. J Bras Nefrol. 2014;36(3):304-14.
Fronza BS, Winkelmann ER, Schneider J, Frizzo MN. Avaliação laboratorial em pacientes com doença renal crônica submetidos à hemodiálise. Rev Bras Anal Clin. 2014;46(1-4):30-6.
Miranda SP, Macedo RN, Júnior GBS, Daher EF. Síndrome síndrome cardiorrenal cardiorrenal: fisiopatologia e tratamento. Rev Assoc Med Bras. 2009;55(1):89-94. http://dx.doi.org/10.1590/S0104-42302009000100022
Gouva C, Nikolopoulos P, Ionnidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int. 2004;66(2):753-60. http://dx.doi.org/10.1111/j.1523-1755.2004.00797.x
Gallagher EJ, Le Roith D, Bloomgarden Z. Review of hemoglobin A1c in the management of diabetes. J Diabetes. 2009;1(1):9-17. http://dx.doi.org/10.1111/j.1753-0407.2009.00009.x
Saudek CD, Brick JC. The clinical use of hemoglobin A1c. J Diabetes Sci Technol. 2009;3(4):629-34. http://dx.doi.org/10.1177/193229680900300402
Saudek CD, Derr RL, Kalyani RR. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA. 2006;295(14):1688-97. http://dx.doi.org/10.1001/jama.295.14.1688
Lynn B, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem. 2001;47(2):153-63.
Schnedl WJ, Liebminger AL, Roller RE, Lipp RW, Krejs GJ. Hemoglobin variants and determination of glycated hemoglobin (HbA1c). Diabetes Metab Res Rev. 2001;17(2):94-8. http://dx.doi.org/10.1002/dmrr.186
Unnikrishnan R, Anjana RM, Mohan V. Drugs affecting HbA1c levels. Indian J Endocrinol Metab. 2012;16(4):528-31. http://dx.doi.org/10.4103/2230-8210.98004
Netto AP, Andriolo A, Filho FF, Tambascia M, Gomes MB, Melo M, Sumita NM, Lyra R, Cavalcanti S. Atualização sobre hemoglobina glicada (HbA1C) para avaliação do controle glicêmico e para o diagnóstico do diabetes: aspectos clínicos e laboratoriais. J Bras Patol Med Lab. 2009;45(1):31-48. http://dx.doi.org/10.1590/S1676-24442009000100007
Ghigo E, Porta M. Diabetes secondary to endocrine and pancreatic disorders, 22ª ed. Switzerland: Karger; 2014.
Mittman N, Desiraju B, Fazil I, Kapupara H, Chattopadhyay J, Jani CM, Avram MM. Serum fructosamine versus glycosylated hemoglobin as an index of glycemic control, hospitalization, and infection in diabetic hemodialysis patients. Kidney Int Suppl. 2010;(117):S41-5. http://dx.doi.org/10.1038/ki.2010.193
Weykamp, CW, Miedema K, De Haan T, Doelman CJA. Carbamylated hemoglobin interference in glycohemoglobin assays. Clin Chem. 1999;45(3):438-40.
Selvaraj N, Bobby Z, Sathiyapriya V. Effect of lipid peroxides and antioxidants on glycation of hemoglobin: an in vitro study on human erythrocytes. Clin Chim Acta. 2006;366(1-2):190-5. http://dx.doi.org/10.1016/j.cca.2005.10.002
Sharif A, Baboolal K. Diagnostic application of the A1c assay in renal disease. J Am Soc Nephrol. 2010;21(3):383-5. http://dx.doi.org/10.1681/ASN.2010010031
Joy MS, Cefalu WT, Hogan SL, Nachman PH. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis. 2002;39(2):297-307. http://dx.doi.org/10.1053/ajkd.2002.30549
Mácsai E, Rakk E, Milénder M, Fulcz A. Significance of hemoglobin A1c in the management of diabetes in dialysis patients. Orv Hetil. 2014;155(36):1421-5. http://dx.doi.org/10.1556/OH.2014.29986
Williams ME, Mittman N, Lin MA, Brennan JI, Mooney A, Johnson CD, Jani CM, Maddux FW, Lacson E. The glycemic indices in dialysis evaluation (GIDE) study: Comparative measures of glycemic control in diabetic dialysis patients. Hemodial Int. 2015;19(4):562-71. http://dx.doi.org/10.1111/hdi.12312
Baker JR, O’Connor JP, Metcalf PA, Lawson MR, Johnson RN. Clinical usefulness of estimation of serum fructosamine concentration as a screening test for diabetes mellitus Br Med J (Clin Res Ed). 1983;287(6396):863-7. http://dx.doi.org/10.1136/bmj.287.6396.863
Kang DS, Park J, Kim JK, Yu J. Clinical usefulness of the measurement of serum fructosamine in childhood diabetes mellitus. Ann Pediatr Endocrinol Metab. 2015;20(1):21-6. http://dx.doi.org/10.6065/apem.2015.20.1.21
Downloads
Published
Issue
Section
License
COPYRIGHT
The submission of originals to Ciência & Saúde implies the transfer by the authors of the right for publication. Authors retain copyright and grant the journal right of first publication. If the authors wish to include the same data into another publication, they must cite Ciência & Saúde as the site of original publication.
CREATIVE COMMONS LICENSE
As this journal is open access, the articles are allowed free use in scientific and educational applications, with citation of the source.
According to the type of Creative Commons License (CC-BY 4.0) adopted by Ciência & Saúde , the user must respect the requirements below.
You are free to:
Share — copy and redistribute the material in any medium or format.
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
However, only under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests Ciência & Saúde endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
For more details on the Creative Commons license, please follow the link in the footer of this website.